TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9100593
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy alone
Study: 2890951
Drug: Dipyridamole 75
Normalized name: dipyridamole 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP‐ASA)
Study: 24957485
Drug: high-dose casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose casein (HP) 51.7 kcal
Study: 24957485
Drug: high-dose sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose sucrose (HC) 51.7 kcal
Study: 24957485
Drug: low-dose casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose casein (LP) 17.2 kcal
Study: 24957485
Drug: low-dose sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose sucrose (LC) 17.2 kcal
Study: 24112417
Drug: 14-week intensive
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-week intensive intervention including breastfeeding benefits, understanding GDM, nutrition and exercise education, coping skills training, physical activity, educational and motivational text messaging, and 3 months of continued monthly contact
Study: 17980497
Drug: Gonadotropin Releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin Releasing Hormone analogue (GnRHa) treatment
Study: 15073842
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and oxaliplatin in combination with infusional 5‐FU/LV
Study: 11842947
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special therapy
Study: 20394254
Drug: Dextromethorphan 90
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 90 mg
Study: 8094308
Drug: Granulocyte-macrophage colony
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony stimulating factor (GM-CSF) at a starting dose of 250 micrograms/m2/day as continuous infusion via the IVC catheter.
Study: 8094308
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg daily) given to both groups.
Study: 8094308
Drug: Mechanical clot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical clot aspiration used for occlusions during GM-CSF therapy.
Study: 3666667
Drug: Pirenzepine 2
Normalized name: pirenzepine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 2 X 25 mg
Study: 3666667
Drug: Pirenzepine 2
Normalized name: pirenzepine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 2 X 50 mg
Study: 10609068
Drug: Single DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single DMARD (methotrexate 7.5‐15 mg/week or sulfasalazine 1‐2 g/day or hydroxychloroquine 200 mg/day)
Study: 10609068
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTX + SSZ or MTX + HCQ
Study: 10609068
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTX + SSZ + HCQ
Study: 7492036
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of IM ketorolac and oral placebo
Study: 7492036
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral indomethacin and IM placebo
Study: 15611975
Drug: Paclitaxel 70
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 70 mg/m² on Days 1 and 8, carboplatin AUC 5 on Day 1, gemcitabine 1000 mg/m² on Days 1 and 8 every 21 days for a maximum of 8 cycles
Study: 9681077
Drug: CAPOMEt (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOMEt (weekly regimen incorporating cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and etoposide)
Study: 7999849
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with rifampin and bacitracin
Study: 30301241
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (450 mL; 2 kcal)
Study: 30301241
Drug: M280 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat; 280 kcal)
Study: 30301241
Drug: M504 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat; 504 kcal)
Study: 30301241
Drug: P280 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: P280 (70 g protein, 0 g carbohydrate, 0 g fat; 280 kcal)
Study: 28177172
Drug: VIBRANT capsule
Normalized name: VIBRANT Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIBRANT capsule treatment for 8 weeks
Study: 28177172
Drug: Sham capsule
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham capsule treatment for 8 weeks
Study: 28177172
Drug: VIBRANT capsule
Normalized name: VIBRANT Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIBRANT capsule treatment
Study: 28177172
Drug: Sham capsule
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham capsule treatment
Study: 19031710
Drug: Colon purification
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon purification treatment
Study: 19031710
Drug: Routine anti‐coma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anti‐coma hepaticum treatments
Study: 12420730
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous metronidazole 500 mg preoperatively
Study: 16362397
Drug: Broad-spectrum multi-drug
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum multi-drug regimen (cefuroxime 1.5 g i.v. and metronidazole 0.5 g i.v. preoperatively, co-amoxiclav 375 mg orally 8-hourly postoperatively for 5 days)
Study: 12921453
Drug: Cephalexin twice
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin twice daily
Study: 12921453
Drug: Cephalexin three
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin three times daily
Study: 3243093
Drug: Cefadroxil once
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil once daily
Study: 11029359
Drug: Thoracoscopic talc
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thoracoscopic talc poudrage (5 g) under local anesthesia
Study: 2580156
Drug: RO 13‐6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13‐6438 10 mg intravenously
Study: 2580156
Drug: RO 13‐6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13‐6438 20 mg intravenously
Study: 2580156
Drug: RO 13‐6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13‐6438 20 mg orally
Study: 2580156
Drug: RO 13‐6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13‐6438 40 mg orally
Study: 2580156
Drug: RO 13‐6438
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 13‐6438 60 mg orally
Study: 31839089
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: periarticular injection of compound analgesics of ropivacaine, ketorolac, adrenaline, morphine and normal saline
Study: 31839089
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: periarticular injection of compound analgesics of bupivacaine, methylprednisolone, adrenaline, morphine and normal saline
Study: 24838902
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure therapy (10 cmH2O)
Study: 20413372
Drug: Calcipotriol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol plus betamethasone dipropionate gel
Study: 20413372
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate (single component in gel vehicle)
Study: 20413372
Drug: Calcipotriol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (single component in gel vehicle)
Study: 17980928
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine with or without OADs
Study: 17980928
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin (once-daily, twice-daily, or more than twice-daily)
Study: 10081632
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg, 20 mg on days 0 and 4)
Study: 18768040
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (group A)
Study: 2127562
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (50 mg 3-times daily)
Study: 380913
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg once daily)
Study: 394280
Drug: Diclofenac (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (25 mg, three times daily for the first week, then four or six tablets in the second week)
Study: 27628045
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 60,000 units 4 weekly (group 1)
Study: 27628045
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 60,000 units 8 weekly (group 2)
Study: 15154938
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 2 g/day for 4 weeks
Study: 12057137
Drug: Radiation given
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy
Study: 8490338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adenoidectomy and ventilation tubes
Study: 3688382
Drug: Vidisic (jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidisic (jelly artificial tear solution)
Study: 3688382
Drug: Dexpanthenol ointment
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol ointment
Study: 20855114
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg RBZ at baseline and months 1, 3, and 5 (group 1)
Study: 20855114
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 mg RBZ and focal or grid laser at baseline and month 3 (group 3)
Study: 18668535
Drug: rilonacept (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept (160 mg weekly subcutaneous injections)
Study: 12008860
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride (Prozac)
Study: 10360845
Drug: Propofol bolus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol bolus dose of 2 mg/kg or 1 mg/kg for those older than 65 years, followed by infusion of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1) of propofol.
Study: 1778191
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release verapamil (SRV) 360 mg
Study: 24512053
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg once daily for 52 weeks
Study: 24512053
Drug: Tofogliflozin 40
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 40 mg once daily for 52 weeks
Study: 24512053
Drug: Tofogliflozin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofogliflozin (doses not specified) in add-on trial
Study: 23216439
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use treatment for AAPIs
Study: 23216439
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use treatment for non-AAPIs (control group)
Study: 19081092
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g L-arginine added to a fatty meal (3 ml cream/kg body weight)
Study: 19081092
Drug: Fatty meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty meal without L-arginine
Study: 19081092
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g phenylalanine added to a fatty meal
Study: 19081092
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g leucine added to a fatty meal
Study: 19081092
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g L-arginine alone (without cream)
Study: 3067950
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control using ultralente insulin as basal cover and soluble insulin at mealtimes
Study: 29329551
Drug: Miniscalpel acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miniscalpel acupuncture treatment
Study: 29329551
Drug: NSAIDs (zaltoprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (zaltoprofen, one oral tablet, three times a day for three weeks)
Study: 29329551
Drug: Miniscalpel acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miniscalpel acupuncture treatment combined with NSAIDs
Study: 12557836
Drug: Chloroquine (CQ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (CQ; 25 mg/kg)
Study: 12557836
Drug: Sulfadoxine-pyrimethamine (SP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP; 25 mg/kg of the sulfadoxine component)
Study: 12557836
Drug: Mefloquine (MQ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (MQ; 15 mg/kg)
Study: 1757038
Drug: Methylprednisolone (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (initially 100 mg daily, reduction every 3 days)
Study: 1757038
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 (100 mg thiamin daily)
Study: 7041939
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CMF)
Study: 6146861
Drug: CMF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF treatment
Study: 30655568
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily for 2 weeks
Study: 30899947
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser combined with basic periodontal therapy
Study: 30899947
Drug: Basic periodontal
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic periodontal therapy
Study: 27593618
Drug: NO3‐ rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3‐ rich beetroot juice (4000 mg/L NO3‐)
Study: 22866961
Drug: Hypocaloric diets
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diets containing different levels of sucrose or high fructose corn syrup (HFCS)
Study: 20354448
Drug: Hourly urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly urine output (HUO, n = 15)
Study: 15494721
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pegylated liposomal doxorubicin (PLD) 45 mg m(‐2) and paclitaxel 150 mg m(‐2), every 28 days for a total of six cycles
Study: 355585
Drug: MPA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (20 mg orally q 8 hr for 32 hr)
Study: 31356678
Drug: Ketoconazole (KTZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTZ) 200 or 400 mg
Study: 31451521
Drug: Intermittent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent low-dose ASA (81 mg daily for one week/placebo for one week)
Study: 31451521
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose ASA (81 mg daily)
Study: 31451521
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (both intermittent and continuous)
Study: 26187121
Drug: Radically Open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radically Open Dialectical Behaviour Therapy (RO-DBT) for 7 months (individual and group treatment)
Study: 21500490
Drug: vitaprost plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitaprost plus in rectal suppositoria for 1 month, then vitaprost forte for 2 months
Study: 11335733
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg/d in 3 daily doses)
Study: 11335733
Drug: Amoxicillin-clavulanate (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (amoxicillin 45 mg/kg/d in 2 daily doses)
Study: 7871042
Drug: Caffeine 600
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 600 mg/70 kg
Study: 29584462
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg caffeine)
Study: 8781869
Drug: Caffeine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (all doses)
Study: 2876879
Drug: Haloperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (20 mg i.m. on the first day and 20 mg p.o. daily from day 2 to 21)
Study: 2876879
Drug: Pipothiazine palmitate
Normalized name: Pipothiazine palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipothiazine palmitate (100 mg i.m. on the first day and daily glass of milk with grenadine from day 2 to 21)
Study: 29798296
Drug: Weisu granules
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weisu granules combined with Lanqin oral solution
Study: 29798296
Drug: Lanqin oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanqin oral solution
Study: 29798296
Drug: Esomeprazole Magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole Magnesium Enteric-coated Tablets and Lanqin oral solution
Study: 25498565
Drug: More rigorous
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More rigorous dose calculation algorithm (DCA)
Study: 25498565
Drug: Laxative as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative as a method of bowel preparation
Study: 21386036
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/5 mg and Ezetimibe
Study: 20423469
Drug: Dietetic counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic counselling (by regular home visits and telephone calls) and oral nutritional supplementation for three months after surgery
Study: 12587819
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose i.v. cyclophosphamide (200‐400 mg per month) and prednisone (mean dose 20.5 mg per day)
Study: 12587819
Drug: Prednisone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (mean dose 20.5 mg per day) only or with antimalarials
Study: 11099587
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) dexamethasone (0.6 mg/kg, maximum 8 mg)
Study: 11099587
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) dexamethasone (0.6 mg/kg, maximum 8 mg)
Study: 10988282
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once daily)
Study: 12241832
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg three times daily)
Study: 3532694
Drug: i.v. diazoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diazoxide (75-150 mg bolus injections)
Study: 3532694
Drug: i.m. dihydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. dihydralazine (6-12.5 mg bolus injections)
Study: 3532694
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with furosemide i.v.
Study: 11314240
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol 50 micrograms/g/ml solution
Study: 11314240
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 1% lotion
Study: 9007116
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of paclitaxel
Study: 9007116
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of paclitaxel
Study: 16381626
Drug: Every-3-week therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-week therapy (200 mg/m2 paclitaxel, AUC 6 mg/mL/min carboplatin, trastuzumab initial 8 mg/kg, subsequent 6 mg/kg every 21 days for 8 cycles)
Study: 16381626
Drug: Weekly therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly therapy (80 mg/m2 paclitaxel, AUC 2 mg/mL/min carboplatin, trastuzumab initial 4 mg/kg, subsequent 2 mg/kg every 4 weeks for 6 cycles)
Study: 16381626
Drug: Weekly therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly therapy
Study: 16381626
Drug: Every-3-week therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-week therapy